GO:0009328 phenylalanine-tRNA ligase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009328 (phenylalanine-tRNA ligase complex) is a cellular_component term describing the enzyme complex that ligates phenylalanine to tRNA(Phe), forming L-phenylalanyl-tRNA(Phe).
• The complex is built around phenylalanyl-tRNA synthetase (PheRS/FARS), a class II aminoacyl-tRNA synthetase that is essential for translation and is conserved from bacteria to humans.
• In mammalian cells, phenylalanyl-tRNA synthetase can associate with the cytoskeletal framework fraction, linking translation machinery to cell architecture.
• PheRS can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, a non-canonical amino acid, which has implications for translational fidelity and disease.
• The complex is a validated drug target in malaria parasites, where bicyclic azetidines inhibit phenylalanine tRNA-synthetase.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of phenylalanine-tRNA ligase complex function in health and disease.
Description
The phenylalanine-tRNA ligase complex (GO:0009328) is the cellular machinery responsible for attaching the amino acid phenylalanine to its cognate transfer RNA, tRNA(Phe), thereby producing L-phenylalanyl-tRNA(Phe) for ribosomal protein synthesis. This enzyme complex, also known as phenylalanyl-tRNA synthetase (PheRS), is a class II aminoacyl-tRNA synthetase and is essential for accurate translation of the genetic code. The complex has been studied biochemically for decades, with early kinetic work on the Escherichia coli enzyme establishing the catalytic mechanism of phenylalanine activation and tRNA charging. The complex is conserved across all domains of life, although archaeal aminoacyl-tRNA synthesis shows diversity that replaces the classical dogma of a single enzyme per amino acid. In mammalian cells, phenylalanyl-tRNA synthetase can be found associated with the cytoskeletal framework fraction, suggesting roles beyond canonical translation. The complex is also of medical interest: in malaria parasites, phenylalanine tRNA-synthetase is a validated drug target inhibited by bicyclic azetidines, and in bacteria and eukaryotes, PheRS can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, a non-proteinogenic amino acid linked to neurological disease. Researchers study GO:0009328 to understand translation fidelity, tRNA charging, and the emerging non-canonical functions of aminoacyl-tRNA synthetases in cell biology and disease.
phenylalanine-tRNA ligase complex At A Glance
| GO ID | GO:0009328 |
|---|---|
| GO term | phenylalanine-tRNA ligase complex |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Catalyzes the ligation of phenylalanine to tRNA(Phe), forming L-phenylalanyl-tRNA(Phe) |
| Enzyme class | Class II aminoacyl-tRNA synthetase (PheRS) |
| Conservation | Found in bacteria, archaea, and eukaryotes |
| Cellular context | Can associate with the cytoskeletal framework fraction in mammalian cells |
| Disease relevance | Drug target in malaria; misaminoacylation linked to disease |
What Is GO:0009328?
GO:0009328 (phenylalanine-tRNA ligase complex) is defined by QuickGO as an enzyme complex that catalyzes the ligation of phenylalanine to tRNA(Phe), forming L-phenylalanyl-tRNA(Phe). In other words, it is the molecular machine that pairs the amino acid phenylalanine with its matching tRNA molecule, a critical step in protein synthesis. The complex is composed of phenylalanyl-tRNA synthetase subunits and is classified under the cellular_component ontology.
Why Is phenylalanine-tRNA ligase complex Important in Cell Biology?
The phenylalanine-tRNA ligase complex is essential for protein synthesis because it ensures that phenylalanine is correctly incorporated into nascent polypeptides. Without accurate charging of tRNA(Phe), translation would produce mistranslated proteins, which can be toxic or nonfunctional. Beyond this canonical role, the complex has been linked to cytoskeletal association in mammalian cells, to drug susceptibility in malaria parasites, and to misaminoacylation with 3,4-dihydroxy-L-phenylalanine, a metabolite relevant to neurological disorders. Understanding GO:0009328 therefore spans basic translation biology, evolutionary diversity of aminoacyl-tRNA synthesis, and therapeutic development.
• Essential for translation: the complex produces L-phenylalanyl-tRNA(Phe), a required substrate for ribosomal protein synthesis.
• Maintains translational fidelity by preventing misincorporation of non-cognate amino acids.
• Conserved across all domains of life, making it a model for studying aminoacyl-tRNA synthetase evolution.
• Associated with the cytoskeletal framework in mammalian cells, suggesting non-canonical roles.
• Validated drug target in malaria parasites, where inhibition of phenylalanine tRNA-synthetase kills the parasite.
• Can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, linking it to disease mechanisms.
• Kinetic and structural studies provide a framework for understanding class II synthetase catalysis.
• CRISPR-based models enable causal testing of gene function in disease contexts.
• Relevant to inherited metabolic and neurological disorders through tRNA charging defects.
• Offers opportunities for antibiotic and antiparasitic drug development.
Structure and Composition of phenylalanine-tRNA ligase complex
Submit composition and architecture
In simple terms: The complex is made of protein subunits that work together to attach phenylalanine to tRNA.
The phenylalanine-tRNA ligase complex is built from phenylalanyl-tRNA synthetase (PheRS) subunits. In bacteria, PheRS is typically a heterotetramer, while eukaryotic and archaeal forms can differ in subunit composition, reflecting the diversity of aminoacyl-tRNA synthesis across domains of life. The complex catalyzes the ligation of phenylalanine to tRNA(Phe) to form L-phenylalanyl-tRNA(Phe).
Association with the cytoskeleton
In simple terms: In mammalian cells, part of the complex can attach to the cell's internal skeleton.
Biochemical fractionation studies have shown that an aminoacyl-tRNA synthetase complex and phenylalanyl-tRNA synthetase associate with the cytoskeletal framework fraction from mammalian cells, indicating that the complex can be anchored to structural elements of the cell. This association may localize translation to specific cellular compartments.
Evolutionary diversity
In simple terms: Different organisms build the complex in different ways.
Archaeal aminoacyl-tRNA synthesis displays diversity that replaces the classical dogma of one enzyme per amino acid, and this diversity extends to phenylalanine-tRNA ligase complex components. Comparative studies across bacteria, archaea, and eukaryotes reveal variations in subunit composition and catalytic properties.
Catalytic core and substrate binding
In simple terms: The complex has a pocket that binds phenylalanine and ATP, then transfers phenylalanine to tRNA.
The catalytic mechanism involves activation of phenylalanine with ATP to form phenylalanyl-adenylate, followed by transfer of phenylalanine to tRNA(Phe). Kinetic investigations of the E. coli enzyme have defined the catalytic reaction steps, and substitution of oxygen by sulfur in ATP affects substrate and ligand binding properties, providing insight into the active site.
Key Genes Involved in GO:0009328 phenylalanine-tRNA ligase complex
The phenylalanine-tRNA ligase complex is encoded by genes for phenylalanyl-tRNA synthetase subunits and associated factors across species.
| Gene | Major Role | Research Relevance |
|---|---|---|
| pheS (E. coli) | Encodes the alpha subunit of phenylalanyl-tRNA synthetase | Model for kinetic and structural studies |
| pheT (E. coli) | Encodes the beta subunit of phenylalanyl-tRNA synthetase | Essential for tRNA charging and cell viability |
| FARS1 (human) | Encodes a subunit of cytoplasmic phenylalanyl-tRNA synthetase | Linked to translation and disease |
| FARS2 (human) | Encodes mitochondrial phenylalanyl-tRNA synthetase | Associated with mitochondrial disease |
| PheRS (malaria parasite) | Phenylalanine tRNA-synthetase | Drug target for bicyclic azetidines |
| PheRS (archaea) | Phenylalanyl-tRNA synthetase | Model for evolutionary diversity |
| tRNA(Phe) | Transfer RNA that accepts phenylalanine | Substrate for charging and fidelity studies |
| ATP | Energy source for amino acid activation | Cofactor in the ligation reaction |
| Phenylalanine | Amino acid substrate | Ligand for the complex |
| 3,4-dihydroxy-L-phenylalanine | Non-canonical amino acid | Misaminoacylation substrate |
| Cytoskeletal framework proteins | Structural anchors | Association with PheRS in mammalian cells |
| Bicyclic azetidines | Chemical inhibitors | Inhibit malaria PheRS |
| Caenorhabditis tropicalis PheRS | Essential tRNA synthetase | Model for selfish genetic element evolution |
| Mitochondrial translation machinery | Protein synthesis in mitochondria | FARS2-related disease |
| Cytoplasmic translation machinery | Protein synthesis in cytosol | FARS1-related disease |
| Aminoacyl-tRNA synthetase complex | Multi-synthetase complex | Association with cytoskeleton |
How Is phenylalanine-tRNA ligase complex Regulated?
The phenylalanine-tRNA ligase complex is regulated at multiple levels. Its expression is tied to the general translational demand of the cell, and in mammalian cells it can associate with the cytoskeletal framework, which may spatially regulate its activity. The complex is also subject to substrate availability, including phenylalanine and ATP levels, and ATP analogs with sulfur substitutions alter substrate and ligand binding, indicating that nucleotide binding is a regulatory node. In parasites, the complex is inhibited by small molecules such as bicyclic azetidines, demonstrating pharmacological regulation. Additionally, misaminoacylation with 3,4-dihydroxy-L-phenylalanine can occur, suggesting that substrate specificity is not absolute and may be modulated by metabolite levels.
phenylalanine-tRNA ligase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FARS2 | Leigh syndrome spectrum disorder | Knockout or point-mutation in cell lines |
| FARS1 | Translation-related disease | Knock-in of patient variants |
| PheRS (Plasmodium) | Malaria | Parasite inhibition assays |
| PheRS (bacteria) | Bacterial infection | Bacterial knockout and mischarging assays |
| C. tropicalis PheRS | Selfish genetic element | Nematode knockout models |
Mitochondrial and neurological disease
Mutations in FARS2, which encodes mitochondrial phenylalanyl-tRNA synthetase, are associated with nuclear gene-encoded Leigh syndrome spectrum disorders, a group of severe mitochondrial diseases. These conditions highlight the importance of the phenylalanine-tRNA ligase complex in mitochondrial translation and energy metabolism.
Infectious disease and drug targeting
In malaria parasites, phenylalanine tRNA-synthetase is a validated drug target, and bicyclic azetidines inhibit the parasite enzyme, offering a potential therapeutic strategy. This demonstrates the complex's relevance to infectious disease.
Misaminoacylation and neurological implications
Bacterial and eukaryotic phenylalanyl-tRNA synthetases can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, a metabolite linked to neurological disorders. This mischarging can lead to protein misfolding and cellular stress, connecting the complex to neurodegeneration.
Evolutionary conflict and genome stability
In Caenorhabditis tropicalis, an essential tRNA synthetase can evolve selfish behavior, disrupting normal function and affecting organismal fitness. This illustrates how the phenylalanine-tRNA ligase complex can be a battleground for genetic conflicts.
From phenylalanine-tRNA ligase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FARS2 required for mitochondrial translation? | CRISPR knockout in human cell lines |
| Does a patient variant impair tRNA charging? | Point-mutation knock-in |
| Can a tag reveal complex localization? | Tagged knock-in |
| Does overexpression alter translation fidelity? | Overexpression cell model |
| Which genes interact with PheRS? | CRISPR library screening |
| What is the effect of PheRS inhibition? | Pharmacological inhibition with bicyclic azetidines |
How to Study the phenylalanine-tRNA ligase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aminoacylation assay | tRNA charging activity | Kinetic characterization |
| ATP analog binding | Nucleotide binding properties | Active site studies |
| X-ray crystallography | Three-dimensional structure | Inhibitor design |
| Mass spectrometry | Protein interactions | Complex composition |
| CRISPR knockout | Gene function | Causal testing |
| Ribo-seq | Translation efficiency | Fidelity studies |
| RNA-seq | Transcriptome changes | Pathway analysis |
Biochemical assays for tRNA charging
Aminoacylation assays measure the formation of L-phenylalanyl-tRNA(Phe) using radiolabeled phenylalanine or ATP. Kinetic studies of the E. coli enzyme have defined the catalytic parameters, and ATP analog studies reveal nucleotide binding properties.
Structural biology
X-ray crystallography and cryo-EM can resolve the structure of the phenylalanine-tRNA ligase complex, as demonstrated for the malaria parasite enzyme with inhibitors. These methods reveal substrate binding pockets and inhibitor interactions.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry can identify proteins associated with the complex, such as cytoskeletal framework components. This helps define the complex's interactome.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to PheRS inhibitors or that are synthetic lethal with PheRS mutations. This approach is powerful for uncovering pathways linked to GO:0009328.
How CRISPR Can Be Used to Study GO:0009328 phenylalanine-tRNA ligase complex
Knockout
CRISPR knockout of FARS1 or FARS2 can abolish phenylalanine-tRNA ligase complex activity, leading to translation defects. These models are useful for studying essentiality and compensatory pathways.
Point Mutation
Introducing patient-specific point mutations into FARS2 via CRISPR base editing or homology-directed repair allows assessment of variant pathogenicity in isogenic backgrounds.
Knock-in
Knock-in of tagged PheRS alleles enables visualization and immunoprecipitation of the complex, revealing its localization and interactions.
Overexpression
Overexpression of wild-type or mutant PheRS can test gain-of-function effects, including misaminoacylation with 3,4-dihydroxy-L-phenylalanine.
How EDITGENE Supports phenylalanine-tRNA ligase complex Research
Researchers studying phenylalanine-tRNA ligase complex-related genes often need to determine whether a candidate gene is causally involved in translation, disease, or drug response. EDITGENE provides CRISPR-based cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for phenylalanine-tRNA ligase complex research.
Frequently Asked Questions About phenylalanine-tRNA ligase complex
What is the phenylalanine-tRNA ligase complex?
It is an enzyme complex (GO:0009328) that catalyzes the ligation of phenylalanine to tRNA(Phe), forming L-phenylalanyl-tRNA(Phe).
What genes are involved in the phenylalanine-tRNA ligase complex?
Key genes include FARS1 and FARS2 in humans, and pheS and pheT in bacteria.
What is the function of GO:0009328?
Its function is to charge tRNA(Phe) with phenylalanine for protein synthesis.
Is the phenylalanine-tRNA ligase complex a drug target?
Yes, in malaria parasites it is targeted by bicyclic azetidines.
How is the phenylalanine-tRNA ligase complex regulated?
It is regulated by substrate availability, cytoskeletal association, and inhibitors.
What diseases are linked to phenylalanine-tRNA ligase complex mutations?
Mutations in FARS2 are linked to Leigh syndrome spectrum disorders.
Can CRISPR be used to study phenylalanine-tRNA ligase complex genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are available.
What is the role of phenylalanyl-tRNA synthetase in translation?
It activates phenylalanine and transfers it to tRNA(Phe), ensuring accurate translation.
Does the phenylalanine-tRNA ligase complex interact with the cytoskeleton?
Yes, in mammalian cells it associates with the cytoskeletal framework fraction.
What is misaminoacylation in the context of PheRS?
It is the incorrect charging of tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine instead of phenylalanine.
Conclusion
The phenylalanine-tRNA ligase complex (GO:0009328) is a fundamental cellular machine required for accurate protein synthesis. Its roles extend beyond translation to cytoskeletal association, drug targeting, and disease, as evidenced by links to mitochondrial disorders and malaria. Continued research using CRISPR models and biochemical assays will further illuminate its mechanisms and therapeutic potential.
References
- 1. Adam MP et al.. 1993. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.. PMID: 26425749
- 2. Bartmann P et al.. 1975. L-phenylalanine:tRNA ligase of Escherichia coli K10. A rapid kinetic investigation of the catalytic reaction.. Biochemistry 14(22):4777-86 PMID: 1101957
- 3. Tumbula D et al.. 1999. Archaeal aminoacyl-tRNA synthesis: diversity replaces dogma.. Genetics 152(4):1269-76 PMID: 10430557
- 4. Tikanova P et al.. 2025. Recurrent evolution of selfishness from an essential tRNA synthetase in Caenorhabditis tropicalis.. Nat Ecol Evol 9(12):2374-2390 PMID: 41249498
- 5. Mirande M et al.. 1985. Association of an aminoacyl-tRNA synthetase complex and of phenylalanyl-tRNA synthetase with the cytoskeletal framework fraction from mammalian cells.. Exp Cell Res 156(1):91-102 PMID: 3880707
- 6. Pimmer J et al.. 1976. L-Phenylalanine: tRNA ligase of Escherichia coli K10. The effect of O replaced by S substitution on substrate and ligand binding properties of ATP.. Eur J Biochem 67(1):171-6 PMID: 786618
- 7. Sharma M et al.. 2021. Structural basis of malaria parasite phenylalanine tRNA-synthetase inhibition by bicyclic azetidines.. Nat Commun 12(1):343 PMID: 33436639
- 8. Moor N et al.. 2011. Bacterial and eukaryotic phenylalanyl-tRNA synthetases catalyze misaminoacylation of tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine.. Chem Biol 18(10):1221-9 PMID: 22035791
